Stock Analysis on Net
Stock Analysis on Net

Illumina Inc. (NASDAQ:ILMN)

This company has been moved to the archive! The financial data has not been updated since November 5, 2021.

Analysis of Liquidity Ratios

Microsoft Excel

Liquidity Ratios (Summary)

Illumina Inc., liquidity ratios

Microsoft Excel
Dec 31, 2020 Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Dec 31, 2016
Current ratio 3.60 6.69 2.49 3.99 3.29
Quick ratio 3.18 6.00 2.23 3.43 2.75
Cash ratio 2.79 5.13 1.95 2.88 2.21

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).


The overall liquidity profile from 2016 to 2020 reflects a consistently strong ability to cover short-term obligations, with all primary liquidity metrics remaining significantly above the standard 1.0 threshold. A pattern of fluctuation is observed, characterized by a substantial spike in liquid reserves during 2019 before a return to more moderate, yet still robust, levels in 2020.

Current Ratio Trends
The current ratio experienced notable volatility, rising from 3.29 in 2016 to a peak of 6.69 in 2019, and subsequently declining to 3.60 in 2020. Throughout the period, the ratio consistently indicates a substantial cushion of current assets over current liabilities.
Quick Ratio Analysis
Moving in tandem with the current ratio, the quick ratio shifted from 2.75 in 2016 to 6.00 in 2019, ending the period at 3.18. The minimal variance between the current and quick ratios suggests that inventories represent a relatively small fraction of the short-term asset base, indicating high quality of liquidity.
Cash Ratio Observations
The cash ratio remained exceptionally high, starting at 2.21 in 2016, peaking at 5.13 in 2019, and concluding at 2.79 in 2020. This suggests a high concentration of cash and cash equivalents, providing a significant margin of safety for immediate debt settlement without relying on the sale of inventory or collection of receivables.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Current Ratio

Illumina Inc., current ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2020 Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Dec 31, 2016
Selected Financial Data (US$ in millions)
Current assets 4,483 4,451 4,490 2,980 2,318
Current liabilities 1,244 665 1,804 746 705
Liquidity Ratio
Current ratio1 3.60 6.69 2.49 3.99 3.29
Benchmarks
Current Ratio, Competitors2
AbbVie Inc. — — — — —
Amgen Inc. — — — — —
Bristol-Myers Squibb Co. — — — — —
Danaher Corp. — — — — —
Eli Lilly & Co. — — — — —
Gilead Sciences Inc. — — — — —
Johnson & Johnson — — — — —
Merck & Co. Inc. — — — — —
Pfizer Inc. — — — — —
Regeneron Pharmaceuticals Inc. — — — — —
Thermo Fisher Scientific Inc. — — — — —
Vertex Pharmaceuticals Inc. — — — — —

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).

1 2020 Calculation
Current ratio = Current assets ÷ Current liabilities
= 4,483 ÷ 1,244 = 3.60

2 Click competitor name to see calculations.


The liquidity position from 2016 to 2020 is characterized by a consistently strong ability to cover short-term obligations, with current assets significantly exceeding current liabilities throughout the analyzed period.

Current Asset Trends
A substantial growth phase occurred between 2016 and 2018, during which current assets increased from 2,318 million USD to 4,490 million USD. Following this expansion, asset levels remained relatively stable, plateauing around the 4.4 billion USD mark through 2020.
Current Liability Volatility
Short-term obligations exhibited significant fluctuation. A notable spike was observed in 2018, where liabilities reached 1,804 million USD. This was followed by a sharp contraction to 665 million USD in 2019, before rising again to 1,244 million USD by the end of 2020.
Current Ratio Analysis
The current ratio demonstrated wide variance, ranging from a low of 2.49 in 2018 to a peak of 6.69 in 2019. The 2018 decline was driven by the aforementioned surge in current liabilities. Conversely, the 2019 peak was the result of stabilized assets coinciding with a sharp reduction in short-term debt. By 2020, the ratio moderated to 3.60, indicating a continued and robust margin of safety for meeting immediate financial commitments.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Quick Ratio

Illumina Inc., quick ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2020 Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Dec 31, 2016
Selected Financial Data (US$ in millions)
Cash and cash equivalents 1,810 2,042 1,144 1,225 735
Short-term investments 1,662 1,372 2,368 920 824
Accounts receivable, net 487 573 514 411 381
Total quick assets 3,959 3,987 4,026 2,556 1,940
 
Current liabilities 1,244 665 1,804 746 705
Liquidity Ratio
Quick ratio1 3.18 6.00 2.23 3.43 2.75
Benchmarks
Quick Ratio, Competitors2
AbbVie Inc. — — — — —
Amgen Inc. — — — — —
Bristol-Myers Squibb Co. — — — — —
Danaher Corp. — — — — —
Eli Lilly & Co. — — — — —
Gilead Sciences Inc. — — — — —
Johnson & Johnson — — — — —
Merck & Co. Inc. — — — — —
Pfizer Inc. — — — — —
Regeneron Pharmaceuticals Inc. — — — — —
Thermo Fisher Scientific Inc. — — — — —
Vertex Pharmaceuticals Inc. — — — — —

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).

1 2020 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 3,959 ÷ 1,244 = 3.18

2 Click competitor name to see calculations.


The analysis of the liquid asset position from 2016 to 2020 reveals a consistently strong capacity to meet short-term obligations. The quick ratio remained well above the standard benchmark of 1.0 throughout the period, indicating a high degree of liquidity and minimal reliance on inventory liquidation to cover current liabilities.

Total Quick Assets Trend
A significant growth phase is observed between 2016 and 2018, where total quick assets increased from US$ 1,940 million to a peak of US$ 4,026 million. Following this period of expansion, the asset base stabilized, maintaining a narrow range around US$ 3,960 million to US$ 3,990 million through 2019 and 2020.
Current Liabilities Volatility
Current liabilities exhibited substantial fluctuations during the five-year period. A notable spike occurred in 2018, with liabilities rising to US$ 1,804 million, followed by a sharp contraction to US$ 665 million in 2019. This volatility recurred in 2020, as liabilities increased again to US$ 1,244 million.
Quick Ratio Dynamics
The quick ratio fluctuated in response to the volatility of current liabilities rather than changes in quick assets. The ratio rose from 2.75 in 2016 to 3.43 in 2017, before declining to 2.23 in 2018 due to the increase in short-term obligations. A significant peak of 6.00 was reached in 2019, driven by the substantial reduction in current liabilities. By 2020, the ratio normalized to 3.18 as liabilities increased once more.

Overall, the financial data indicates a robust liquidity profile. Despite the periodic instability in current liabilities, the maintenance of a quick ratio consistently above 2.0 suggests that the organization possesses ample liquid resources to manage its immediate financial commitments.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Cash Ratio

Illumina Inc., cash ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2020 Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Dec 31, 2016
Selected Financial Data (US$ in millions)
Cash and cash equivalents 1,810 2,042 1,144 1,225 735
Short-term investments 1,662 1,372 2,368 920 824
Total cash assets 3,472 3,414 3,512 2,145 1,559
 
Current liabilities 1,244 665 1,804 746 705
Liquidity Ratio
Cash ratio1 2.79 5.13 1.95 2.88 2.21
Benchmarks
Cash Ratio, Competitors2
AbbVie Inc. — — — — —
Amgen Inc. — — — — —
Bristol-Myers Squibb Co. — — — — —
Danaher Corp. — — — — —
Eli Lilly & Co. — — — — —
Gilead Sciences Inc. — — — — —
Johnson & Johnson — — — — —
Merck & Co. Inc. — — — — —
Pfizer Inc. — — — — —
Regeneron Pharmaceuticals Inc. — — — — —
Thermo Fisher Scientific Inc. — — — — —
Vertex Pharmaceuticals Inc. — — — — —

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).

1 2020 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 3,472 ÷ 1,244 = 2.79

2 Click competitor name to see calculations.


An analysis of the liquidity position from 2016 to 2020 reveals a consistently strong ability to cover short-term obligations using cash assets. Total cash assets exhibited a significant upward trajectory in the early part of the period, more than doubling from 1,559 million US$ in 2016 to 3,512 million US$ in 2018, before stabilizing between 3,414 million US$ and 3,472 million US$ in the subsequent two years.

Cash Ratio Volatility
The cash ratio experienced notable fluctuations, ranging from a low of 1.95 in 2018 to a peak of 5.13 in 2019. This volatility is primarily attributed to significant shifts in current liabilities rather than fluctuations in the cash balance itself.
Liability Trends
Current liabilities showed substantial instability throughout the period. A significant spike occurred in 2018, reaching 1,804 million US$, which caused the cash ratio to dip to its period low. This was followed by a sharp reduction to 665 million US$ in 2019, resulting in the highest observed cash ratio, before liabilities increased again to 1,244 million US$ by the end of 2020.
Liquidity Solvency
Despite the fluctuations in current liabilities, the cash ratio remained consistently and substantially above 1.0. This indicates a robust liquidity profile where the organization maintained sufficient cash and cash equivalents to settle all current liabilities immediately without needing to liquidate other current assets or seek external financing.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?